Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.

Lewandowski LB, Schanberg LE, Thielman N, Phuti A, Kalla AA, Okpechi I, Nourse P, Gajjar P, Faller G, Ambaram P, Reuter H, Spittal G, Scott C.

Lupus. 2016 Aug 3. pii: 0961203316660625. [Epub ahead of print]

PMID:
27488473
2.

The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims.

Garris C, Shah M, Farrelly E.

Cost Eff Resour Alloc. 2015 May 6;13:9. doi: 10.1186/s12962-015-0034-z. eCollection 2015.

3.

Genetic risk factors for thrombosis in systemic lupus erythematosus.

Kaiser R, Li Y, Chang M, Catanese J, Begovich AB, Brown EE, Edberg JC, McGwin G Jr, Alarcón GS, Ramsey-Goldman R, Reveille JD, Vilá LM, Petri MA, Kimberly RP, Taylor KE, Criswell LA.

J Rheumatol. 2012 Aug;39(8):1603-10. doi: 10.3899/jrheum.111451. Epub 2012 Jun 15.

4.

Three decades of progress in treating childhood-onset lupus nephritis.

Pereira T, Abitbol CL, Seeherunvong W, Katsoufis C, Chandar J, Freundlich M, Zilleruelo G.

Clin J Am Soc Nephrol. 2011 Sep;6(9):2192-9. doi: 10.2215/CJN.00910111. Epub 2011 Jul 28.

5.

MHC region and risk of systemic lupus erythematosus in African American women.

Ruiz-Narvaez EA, Fraser PA, Palmer JR, Cupples LA, Reich D, Wang YA, Rioux JD, Rosenberg L.

Hum Genet. 2011 Dec;130(6):807-15. doi: 10.1007/s00439-011-1045-2. Epub 2011 Jun 22.

6.

Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Weckerle CE, Franek BS, Kelly JA, Kumabe M, Mikolaitis RA, Green SL, Utset TO, Jolly M, James JA, Harley JB, Niewold TB.

Arthritis Rheum. 2011 Apr;63(4):1044-53. doi: 10.1002/art.30187.

7.

Spontaneous lupus-like syndrome in HLA-DQ2 transgenic mice with a mixed genetic background.

Rashtak S, Marietta E, Cheng S, Camilleri M, Pittelkow M, David C, Grande J, Murray J.

Lupus. 2010 Jun;19(7):815-29. doi: 10.1177/0961203309360546. Epub 2010 Feb 8.

8.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG.

Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.

9.

Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies.

Harley IT, Kaufman KM, Langefeld CD, Harley JB, Kelly JA.

Nat Rev Genet. 2009 May;10(5):285-90. doi: 10.1038/nrg2571. Review.

10.

Why can't we find a new treatment for SLE?

Eisenberg R.

J Autoimmun. 2009 May-Jun;32(3-4):223-30. doi: 10.1016/j.jaut.2009.02.006. Epub 2009 Mar 28. Review.

11.

Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII).

Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS.

Lupus. 2008 Apr;17(4):314-22. doi: 10.1177/0961203307087875.

12.

Identification of two independent risk factors for lupus within the MHC in United Kingdom families.

Fernando MM, Stevens CR, Sabeti PC, Walsh EC, McWhinnie AJ, Shah A, Green T, Rioux JD, Vyse TJ.

PLoS Genet. 2007 Nov;3(11):e192.

Supplemental Content

Support Center